Watanabe Satoshi

ワタナベサトシ | Watanabe Satoshi

Affiliation and department：

Research field (1)： Tumor diagnostics and therapeutics

Research keywords (3)：腫瘍免疫 , 腫瘍 , 呼吸器

Research theme for competitive and other funds (6)：

2019 - 2023 メガリンを標的とした薬剤性腎障害治療戦略の開発
2015 - 2018 Novel antitumor immunotherapy via immune reconstitution after chemotherapy for advanced lung cancer
2012 - 2015 Search of the effect predictive factor in molecules target therapy for lung cancer
2012 - 2015 Novel tumor immunotharapy for advanced lung cancer using homeostatic reconstitution of antitumor immunity
2009 - 2011 Development of system to predict postoperative recurrence of lung cancer/order-made treatment using peripheral blood circukationg tumor cell

Show all

Papers (222)：

Tetsuhiko Asao, Takehito Shukuya, Kohei Uemura, Rui Kitadai, Gaku Yamamoto, Atsuto Mouri, Meiyo Tamaoka, Ryosuke Imai, Yoko Tsukita, Kazutoshi Isobe, et al. Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047). Lung cancer (Amsterdam, Netherlands). 2024. 194. 107894-107894
Naohiro Yanagimura, Satoshi Watanabe, Toshiaki Kikuchi. Combined PARP and PD-L1 inhibition: a promising treatment option for relapsed small-cell lung cancer. Journal of thoracic disease. 2024. 16. 6. 4075-4078
Satoshi Watanabe, Toshiaki Kikuchi. Does Autoimmune Response Against Surfactant Protein Cause Interstitial Lung Disease?. American journal of respiratory and critical care medicine. 2024
有波純, 柳村尚寛, 関谷友樹, 有田将史, 大坪亜矢, 田中知宏, 野嵜幸一郎, 才田優, 近藤利恵, 渡部聡, et al. 当院におけるMET遺伝子変異陽性非小細胞肺癌に対するテポチニブ療法に関する後方視的検討. 肺癌. 2024. 64. 3. 257-257
Masahiro Yanagiya, Yoshihiro Kazama, Shun-Mao Yang, Amos Lal, Debora Russo, Satoshi Watanabe, Ami Wada, Yoshiaki Furuhata, Jun Nakajima. Intrapleural minocycline pleurodesis for bilateral pneumothorax due to septic pulmonary embolism: a case report. Journal of thoracic disease. 2024. 16. 5. 3493-3502

ｍore...

MISC (142)：

桝田尚明, 渡部聡, 菖野邦浩, 鈴木遼, 関谷友樹, 大坪亜矢, 田中知宏, 野嵜幸一郎, 才田優, 近藤利恵, et al. 非小細胞肺癌のサルコペニア患者に対する免疫療法の効果に関わる網羅的蛋白解析(Comprehensive protein analysis of the effect of immunotherapy in non-small cell lung cancer patients with sarcopenia). 日本癌学会総会記事. 2023. 82回. 848-848
森本健司, 山田忠明, 平井聡一, 片山勇輝, 國政啓, 佐々木高明, 西田真, 渡部聡, 塩津伸介, 西岡直哉, et al. AXLシグナル活性化によるKRAS-G12C阻害薬の初期治療抵抗性機構の解明と治療法開発. 日本肺癌学会学術集会号. 2023. 64th (CD-ROM)
大坪亜矢, 後藤優佳, 鈴木遼, 庄子聡, 島賢治郎, 田中知宏, 野嵜幸一郎, 才田優, 木村陽介, 穂苅諭, et al. 分子標的薬を安全に使用できたEGFR遺伝子変異陽性肺癌合併妊娠の一例. 肺癌. 2022. 62. 6. 725-725
解良恭一, 山田忠明, 吉村彰紘, 安宅信二, 谷口寛和, 渡部聡, 三浦理, 山口博之, 内野順治, 高山浩一, et al. AXL expressin within tumor cells in patiens with EGFR-positive lung cancer who received EGFR-TKI. 日本呼吸器学会誌(Web). 2021. 10
Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Hirokazu Taniguchi, Keiko Tanimura, Yuki Katayama, Akihiro Yoshimura, Satoshi Watanabe, Toshiaki Kikuchi, Shinsuke Shiotsu, et al. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. 26. 9. 2244-2256

ｍore...

Professional career (1)：

医学博士 (新潟大学)

Association Membership(s) (8)：

Japanese society of medical oncology , International association for the study of lung cancer , American association for cancer research , THE JAPANESE CANCER ASSOCIATION , THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY , THE JAPAN LUNG CANCER SOCIETY , THE JAPANESE RESPIRATORY SOCIETY , THE JAPANESE SOCIETY OF INTERNAL MEDICINE

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page